EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy

Anna M De Kort iD, H Bea Kuiperij iD, Tainá M Marques iD, Lieke Jäkel iD, Emma van den Berg iD, Iris Kersten, Hugo E P van Berckel-Smit, Marco Duering iD, Erik Stoops, Wilson F Abdo iD, Ingeborg Rasing iD, Sabine Voigt iD und 10 weitere

Annals of Neurology · 2023

DOI: 10.1002/ana.26610 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, 2023. Verfasst von Anna M De Kort und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, Familial, Cerebral Amyloid Angiopathy, Alzheimer Disease. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Eli Lilly and Company, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Vascular amyloid β (Aβ) accumulation is the hallmark of cerebral amyloid angiopathy (CAA). The composition of cerebrospinal fluid (CSF) of CAA patients may serve as a diagnostic biomarker of CAA. We studied the diagnostic potential of the peptides Aβ38, Aβ40, Aβ42, and Aβ43 in patients with sporadic CAA (sCAA), hereditary Dutch‐type CAA (D‐CAA), and Alzheimer disease (AD).

Methods

Aβ peptides were quantified by immunoassays in a discovery group (26 patients with sCAA and 40 controls), a validation group (40 patients with sCAA, 40 patients with AD, and 37 controls), and a group of 22 patients with D‐CAA and 54 controls. To determine the diagnostic accuracy, the area under the curve (AUC) was calculated using a receiver operating characteristic curve with 95% confidence interval (CI).

Results

We found decreased levels of all Aβ peptides in sCAA patients and D‐CAA patients compared to controls. The difference was most prominent for Aβ42 (AUC of sCAA vs controls for discovery: 0.90, 95% CI = 0.82–0.99; for validation: 0.94, 95% CI = 0.89–0.99) and Aβ43 (AUC of sCAA vs controls for discovery: 0.95, 95% CI = 0.88–1.00; for validation: 0.91, 95% CI = 0.83–1.0). All Aβ peptides except Aβ43 were also decreased in sCAA compared to AD (CSF Aβ38: AUC = 0.82, 95% CI = 0.71–0.93; CSF Aβ40: AUC = 0.88, 95% CI = 0.80–0.96; CSF Aβ42: AUC = 0.79, 95% CI = 0.66–0.92).

Interpretation

A combined biomarker panel of CSF Aβ38, Aβ40, Aβ42, and Aβ43 has potential to differentiate sCAA from AD and controls, and D‐CAA from controls. ANN NEUROL 2023;93:1173–1186

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid Angiopathy, FamilialCerebral Amyloid AngiopathyAlzheimer DiseaseHumansAmyloid beta-PeptidesPeptide FragmentsBiomarkers

Substanzen

Amyloid beta-PeptidesPeptide FragmentsBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Nijmegen, the Netherlands.
  • Medical Image Analysis Center and Qbig, Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
  • ADx NeuroSciences, Ghent, Belgium.
  • Department of Intensive Care, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Anna M De Kort, H Bea Kuiperij, Tainá M Marques, Lieke Jäkel, Emma van den Berg, Marco Duering, Wilson F Abdo, Ingeborg Rasing, Sabine Voigt, Emma A Koemans, Kanishk Kaushik, Andrew Davock Warren, Gunnar Brinkmalm, Gisela M Terwindt, Marieke J H Wermer, Floris H B M Schreuder, Catharina J M Klijn, Marcel M Verbeek

Förderung

  • NINDS NIH HHS
  • Eli Lilly and Company
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • National Institutes of Health
  • Stichting Dioraphte
  • Teva Pharmaceutical Industries
  • ZonMw

Zitieren

APA

De Kort, A. M., Kuiperij, H. B., Marques, T. M., Jäkel, L., van den Berg, E., Kersten, I., van Berckel-Smit, H. E. P., Duering, M., Stoops, E., Abdo, W. F., Rasing, I., Voigt, S., Koemans, E. A., Kaushik, K., Warren, A. D., Greenberg, S. M., Brinkmalm, G., Terwindt, G. M., Wermer, M. J. H., …, & Verbeek, M. M. (2023). Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Annals of Neurology. https://doi.org/10.1002/ana.26610

Vancouver

De Kort AM, Kuiperij HB, Marques TM, Jäkel L, van den Berg E, Kersten I, et al. Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy. Annals of Neurology. 2023. doi:10.1002/ana.26610

BibTeX
@article{DeKort2023,
  author = {De Kort, Anna M and Kuiperij, H Bea and Marques, Tainá M and Jäkel, Lieke and van den Berg, Emma and Kersten, Iris and van Berckel-Smit, Hugo E P and Duering, Marco and Stoops, Erik and Abdo, Wilson F and Rasing, Ingeborg and Voigt, Sabine and Koemans, Emma A and Kaushik, Kanishk and Warren, Andrew Davock and Greenberg, Steven M and Brinkmalm, Gunnar and Terwindt, Gisela M and Wermer, Marieke J H and Schreuder, Floris H B M and Klijn, Catharina J M and Verbeek, Marcel M},
  title = {Decreased Cerebrospinal Fluid Amyloid β 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy},
  journal = {Annals of Neurology},
  year = {2023},
  doi = {10.1002/ana.26610}
}
Kostenlos starten →